{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:08:04Z","timestamp":1784092084026,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04714-4","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:44:23Z","timestamp":1784090663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive genomic profiling and tumor mutational burden in parathyroid carcinoma: a nationwide real-world study from Japan"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-7683","authenticated-orcid":false,"given":"Yuko","family":"Takano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyone","family":"Kikumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-2297","authenticated-orcid":false,"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"4714_CR1","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.beem.2024.101966","volume":"39","author":"A Viswanath","year":"2025","unstructured":"A. Viswanath, E.E. Drakou, F. Lajeunesse-Trempe, A.B. Grossman, G.K. Dimitriadis, Parathyroid carcinoma: new insights. Best Pract. Res. Clin. Endocrinol. Metab. 39, 101966 (2025). https:\/\/doi.org\/10.1016\/j.beem.2024.101966","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"4714_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1634\/theoncologist.2018-0334","volume":"24","author":"H Kang","year":"2019","unstructured":"H. Kang, D. Pettinga, A.D. Schubert, P.W. Ladenson, D.W. Ball, J.H. Chung, A.B. Schrock, R. Madison, G.M. Frampton, P.J. Stephens, et al., Genomic profiling of parathyroid carcinoma reveals genomic alterations suggesting benefit from therapy. Oncologist. 24, 791\u2013797 (2019). https:\/\/doi.org\/10.1634\/theoncologist.2018-0334","journal-title":"Oncologist"},{"key":"4714_CR3","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1002\/ijc.33166","volume":"147","author":"Y Hu","year":"2020","unstructured":"Y. Hu, X. Zhang, O. Wang, Y. Bi, X. Xing, M. Cui, M. Wang, W. Tao, Q. Liao, Y. Zhao, The genomic profile of parathyroid carcinoma based on whole-genome sequencing. Int. J. Cancer. 147, 2446\u20132457 (2020). https:\/\/doi.org\/10.1002\/ijc.33166","journal-title":"Int. J. Cancer"},{"key":"4714_CR4","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1056\/NEJMoa031237","volume":"349","author":"TM Shattuck","year":"2003","unstructured":"T.M. Shattuck, S. V\u00e4lim\u00e4ki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, M.E. Wierman, K. Tojo, C.M. Robbins, J.D. Carpten, et al., Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722\u20131729 (2003). https:\/\/doi.org\/10.1056\/NEJMoa031237","journal-title":"N. Engl. J. Med."},{"key":"4714_CR5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"T. Kohno, M. Kato, S. Kohsaka, T. Sudo, I. Tamai, Y. Shiraishi, Y. Okuma, D. Ogasawara, T. Suzuki, T. Yoshida et al., C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov. 12, 2509\u20132515 (2022). https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0417","journal-title":"Cancer Discov."},{"key":"4714_CR6","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"A.M. Goodman, S. Kato, L. Bazhenova, S.P. Patel, G.M. Frampton, V. Miller, P.J. Stephens, G.A. Daniels, R. Kurzrock, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017). https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386","journal-title":"Mol. Cancer Ther."},{"key":"4714_CR7","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"A. Marabelle, M. Fakih, J. Lopez, M. Shah, R. Shapira-Frommer, K. Nakagawa, H.C. Chung, H.L. Kindler, J.A. Lopez-Martin, W.H. Miller et al., Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020). https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9","journal-title":"Lancet Oncol."},{"key":"4714_CR8","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1038\/ncomms6433","volume":"5","author":"JH Jo","year":"2014","unstructured":"J.H. Jo, T.M. Chung, H. Youn, J.Y. Yoo, Cytoplasmic parafibromin\/hCDC73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis. Nat. Commun. 5, 5433 (2014). https:\/\/doi.org\/10.1038\/ncomms6433","journal-title":"Nat. Commun."},{"key":"4714_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ng.2503","volume":"45","author":"C Palles","year":"2013","unstructured":"C. Palles, J.B. Cazier, K.M. Howarth, E. Domingo, A.M. Jones, P. Broderick, Z. Kemp, S.L. Spain, E. Guarino, I. Salguero, et al., Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136\u2013144 (2013). https:\/\/doi.org\/10.1038\/ng.2503","journal-title":"Nat. Genet."},{"key":"4714_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"R.M. Samstein, C.H. Lee, A.N. Shoushtari, M.D. Hellmann, R. Shen, Y.Y. Janjigian, D.A. Barron, A. Zehir, E.J. Jordan, A. Omuro et al., Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019). https:\/\/doi.org\/10.1038\/s41588-018-0312-8","journal-title":"Nat. Genet."},{"key":"4714_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1507\/endocrj.EJ24-0126","volume":"71","author":"H Katoh","year":"2024","unstructured":"H. Katoh, T. Mitsuma, R. Okamoto, K. Naito, T. Tokito, M. Kikuchi, T. Sangai, Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature. Endocr. J. 71, 1069\u20131075 (2024). https:\/\/doi.org\/10.1507\/endocrj.EJ24-0126","journal-title":"Endocr. J."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04714-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04714-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:44:38Z","timestamp":1784090678000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04714-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4714"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04714-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Nagoya University Hospital (approval number: 2022\u20130025) and the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) Data Use Committee (approval number: CDU2022\u2013030\u00a0N).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YT has received honoraria for lectures from MSD K.K. and Chugai Pharmaceutical Co., Ltd. YA received research grants from Chugai Pharmaceutical Co., Ltd. and honoraria for lectures from Konica Minolta REALM, Inc., MSD K.K., and Chugai Pharmaceutical Co., Ltd. The authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"238"}}